[go: up one dir, main page]

AU1133901A - Method of treating metabolic disorders - Google Patents

Method of treating metabolic disorders

Info

Publication number
AU1133901A
AU1133901A AU11339/01A AU1133901A AU1133901A AU 1133901 A AU1133901 A AU 1133901A AU 11339/01 A AU11339/01 A AU 11339/01A AU 1133901 A AU1133901 A AU 1133901A AU 1133901 A AU1133901 A AU 1133901A
Authority
AU
Australia
Prior art keywords
metabolic disorders
treating metabolic
treating
disorders
metabolic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU11339/01A
Inventor
Beth Dunning
Michele Pongowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU1133901A publication Critical patent/AU1133901A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU11339/01A 1999-10-08 2000-10-06 Method of treating metabolic disorders Abandoned AU1133901A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41530799A 1999-10-08 1999-10-08
US41530899A 1999-10-08 1999-10-08
US09415308 1999-10-08
US09415307 1999-10-08
PCT/EP2000/009816 WO2001026639A2 (en) 1999-10-08 2000-10-06 Pharmaceutical composition of ateglinide and another antidiabeticagent

Publications (1)

Publication Number Publication Date
AU1133901A true AU1133901A (en) 2001-04-23

Family

ID=27022945

Family Applications (1)

Application Number Title Priority Date Filing Date
AU11339/01A Abandoned AU1133901A (en) 1999-10-08 2000-10-06 Method of treating metabolic disorders

Country Status (3)

Country Link
EP (1) EP1218015A2 (en)
AU (1) AU1133901A (en)
WO (1) WO2001026639A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1295609A4 (en) * 2000-02-24 2004-11-03 Takeda Chemical Industries Ltd DRUGS CONTAINING COMBINED ACTIVE INGREDIENTS
CZ20023121A3 (en) * 2000-03-17 2003-05-14 Ajinomoto Co., Inc. Pharmaceutical preparations intended for treating diabetic complications and neuropathy and use of such preparations
CA2439063A1 (en) * 2001-03-12 2002-09-19 Novartis Ag Combination of nateglinide or repaglinide with at least one further antidiabetic compound
DK1397124T3 (en) * 2001-06-20 2007-04-02 Merck Sante Sas Use of diabetic agents for the manufacture of a medicament having a healing effect
WO2003076393A1 (en) * 2002-03-11 2003-09-18 Novartis Ag Salts of nateglinide
ES2359910T3 (en) * 2002-05-28 2011-05-30 Ajinomoto Co., Inc. MEDICINAL COMPOSITION TO INHIBIT THE EXPRESSION OF ATP-CITRATE LIASA AND ITS USE.
WO2005092319A1 (en) * 2004-03-29 2005-10-06 Ranbaxy Laboratories Limited Rapidly disintegrating pharmaceutical compositions comprising nateglinide and a disintegrant
CN101756971B (en) * 2008-10-09 2013-09-18 北京德众万全药物技术开发有限公司 Oral solid drug composition of metformin hydrochloride repaglinide
CN107106583B (en) * 2015-06-05 2021-04-13 台中荣民总医院 Pharmaceutical composition comprising acarbose and use thereof for immunomodulation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes

Also Published As

Publication number Publication date
WO2001026639A3 (en) 2002-01-10
EP1218015A2 (en) 2002-07-03
WO2001026639A2 (en) 2001-04-19

Similar Documents

Publication Publication Date Title
AU2001249881A1 (en) Method of treating the heart
AU6578998A (en) Method of treatment of migraine
HU0001471D0 (en) New method of treatment
AU3977700A (en) Method of treating neurological disorders
AU5042000A (en) Methods of treating proliferative disorders
AU4552200A (en) Method of treating psychotic disorders
AU1133901A (en) Method of treating metabolic disorders
AU3757300A (en) Method of treating anxiety disorders
AU1735800A (en) Method of treating seizure disorders
AU2080201A (en) Treatment of addiction disorders
AU1282099A (en) Method for treatment of disorders of attention
AU3753500A (en) Methods of treating fibrinogen-related disorders
AUPP508798A0 (en) Method of treating psoriasis
AU5861700A (en) Method of threading
AU4598400A (en) Method of treatment
GB9930688D0 (en) Novel method of treatment
AU2002257569A1 (en) Method of treating metabolic disorders using neuronatin polypeptides
AU2382601A (en) Novel method of treatment
AU8031700A (en) Method of treating fibrosis
AU1784701A (en) Method of treating neuroblastoma
AU2001236909A1 (en) Method of treating disorders of the eye
AUPQ080999A0 (en) Method of treatment
AUPQ233299A0 (en) Method of treatment
AUPQ320299A0 (en) Method of treatment
AUPQ234499A0 (en) Method of treating liver diseases

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase